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INTRAPERITONEAL CHEMOTHERAPY FOR THE TREATMENT OF MALIGNANT PERITONEAL
MESOTHELIOMA. Joshua Leinwand, Binsheng Zhao, Sharyn Lewin, John Allendorf, John Chabot,
Lawrence Schwartz and Robert Taub. Department of Medicine, Columbia University College of Physicians
and Surgeons, New York, NY. (Sponsored by Elena Ratner, Department of Obstetrics, Gynecology &
Reproductive Sciences, Yale University School of Medicine, New Haven, CT.)
Our treatment protocol for malignant peritoneal mesothelioma (MPM) includes initial
cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC), outpatient catheter-administered
intraperitoneal chemotherapy (CAIPEC), and a second cytoreductive surgery with HIPEC. We
hypothesized that even distribution of CAIPEC would correlate with better overall survival and fewer side
effects; that the pharmacokinetics of HIPEC would be influenced by body surface area (BSA); and that
tissue penetration of CAIPEC would exceed that of HIPEC due to the longer dwell time.
We analyzed CT peritoneograms from 38 MPM patients undergoing cisplatin CAIPEC for volume
and surface area, and modeled overall survival and post-treatment glomerular filtration rate (GFR) with
these as predictors. We collected intraoperative blood and peritoneal fluid samples from 10 patients
undergoing oxaliplatin HIPEC, used mass spectrometry to determine fluid platinum levels and modeled
these outcomes with BSA as a predictor. We collected intraoperative peritoneal tissue samples from 6
patients undergoing HIPEC and used x-ray fluorescence microscopy to characterize tissue platinum levels.
Decreased mortality was associated with larger surface areas (p=0.02) and smaller volumes of
CAIPEC (p=0.03), controlling for age, sex, histologic subtype, and residual disease >0.5cm. Larger
volumes were associated with higher post-treatment GFR, controlling for pre-treatment GFR, BSA, surface
area and BSA-volume interaction (p=0.02). Higher BSA was associated with lower plasma oxaliplatin
(p=0.01), and greater pharmacokinetic advantage (p=0.02). Tissue platinum was highest at second surgery
post-HIPEC, lowest at first surgery post-HIPEC, and intermediate at second surgery pre-HIPEC.
CT peritoneography provides parameters associated with overall survival and post-treatment GFR
in MPM patients undergoing CAIPEC. In HIPEC patients who receive a BSA-based oxaliplatin dose and
carrier fluid volume titrated to achieve a desired flow rate, BSA is a predictor of systemic drug exposure.
The direct tissue penetration depth of platinum attributable to multiple courses of CAIPEC is greater, and
the tissue distribution of platinum more homogeneous, than that attributable to a single dose of HIPEC.
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I. Introduction
Biodistribution of Intraperitoneal Chemotherapy
Intraperitoneal (IP) administration of chemotherapy has been used to treat peritoneal
surface-spreading malignancies in order to maximize local concentrations while
minimizing systemic toxicities. This rationale is supported by pharmacokinetic studies
describing the “pharmacokinetic advantage” of IP administration of various drugs: the
ratio of intraperitoneal to intravascular drug distribution, expressed either in peak
concentration or area under the concentration-time curve (AUC).(1-13) The peak and
AUC pharmacokinetic advantages of several commonly-used agents are listed in Table 1.
Intraperitoneal chemotherapy is instilled in a carrier fluid, which in most cases is normal
saline or lactated Ringer’s solution. The major exception is oxaliplatin, which, due to its
instability in chloride-containing solutions, is frequently diluted in 5% dextrose. (14) As
in intravenous chemotherapy, the dose of chemotherapy during IP chemotherapy is
usually calculated based on body surface area (BSA).(15) Some institutions dilute the
drug in a standard volume of carrier fluid, some calculate carrier fluid volume based on
BSA, and some titrate carrier fluid volume to achieve a desired flow rate during
hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC).(15-17) As a result,
there is variability between patients in the concentration of oxaliplatin in the perfusate.
Likewise, the duration of chemoperfusion has not been standardized; perfusion times
range from 30 minutes to 2 hours.(15, 18)
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Table 1. Pharmacokinetic advantage associated with intraperitoneal delivery of selected
antineoplastic agents.

Drug

Peak intraperitoneal to

AUC intraperitoneal to

intravascular drug ratio

intravascular drug ratio

Carboplatin

---

18

Cisplatin

20

12

Cytarabine

664

474

Doxorubicin

474

---

5-fluorouracil

298

367

Floxuridin

---

1000

Melphalan

93

65

Methotrexate

92

---

Mitoxantrone

---

1400

Paclitaxel

1000

1000

AUC, Area under the concentration-time curve. Adapted from Markman 2007.(19)
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Experimental measurements of tissue concentrations of locally-administered
chemotherapy drugs compared to distance from tissue surface have been reported in
tumor spheroids in vitro, and in IP-administration in mice and rats.(20-25) These have
found the greatest drug accumulation at the tissue surface, with concentrations decreasing
dramatically with distance from the tissue surface after drug dwell times ranging from 1
to 168 hours. A study of HIPEC, administered over 90 minutes to ovarian carcinoma
patients, comparing antibody-based detection of DNA-cisplatin adducts in ovarian
carcinoma tumor nodules versus buccal cells (as a control for systemic exposure),
likewise found greater adduct formation in the tumor nodules only to a distance of 5mm
from the peritoneal surface.(26)
A mathematical model estimated a direct tissue penetration distance on the order of
0.5mm for a one-time, limited-dwell IP administration of normothermic cisplatin; this
distance increased to approximately 3-5mm with hyperthermic (43˚C) administration.(27)
These values were based on an exponential decay of drug concentration within peritoneal
tissues as a function of distance from the peritoneal surface, which is modeled to
asymptotically approach the circulation drug concentration.
However, the previous studies and models concern IP administration with drug removal
at a set end point, and may not be applicable to longer dwell-times, in which there is
experimental evidence of greater tissue penetration and tumor drug concentration. The
advantage in tumor cisplatin concentration of IP over IV administration in rats was only
realized after 24 hours of dwell-time.(21) Tumor platinum concentration does not peak
until at least 24 hours after IP instillation, and its ratio to plasma concentration increases
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over at least the first 7 days, as drug remains in the peritoneal fluid for at least that long
while it is cleared from the circulation.(22) Furthermore, for IP cisplatin and oxaliplatin
after 24 hour dwell-times, platinum concentration does not appear to decay exponentially
as a function of distance from the peritoneal surface, but to decrease linearly – suggesting
that over longer dwell-times, the diffusion of drug from peritoneal fluid through
peritoneal tissues to the systemic circulation may reach steady state.(28) Theoretically, at
steady state, the concentration of drug may remain higher throughout the peritoneal tissue
than the circulation, as the major obstacle to drug diffusion is the endothelial barrier.(29)
For these reasons, it is important to distinguish between the biodistribution of limiteddwell versus indefinite-dwell IP chemotherapy.
Modalities of Intraperitoneal Chemotherapy Administration

Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC)
Various protocols have been described for the administration of HIPEC. In general,
chemotherapy is instilled intraoperatively after tumor debulking. The drug is heated to
40-43˚C and administered over 60-120 minutes, after which time it is removed from the
peritoneal cavity.(30) Open, closed, and partially-closed techniques have been described,
with different methods to maintain flow in order to preserve hyperthermia and to ensure
even fluid distribution and maximal contact of the instilled drug with the peritoneal
surfaces.(31-33) One study found dye distribution and temperature were most
homogeneous using the open technique.(34) However, there is no evidence that different
HIPEC techniques result in differences in survival.(35-37)
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Intraoperative IP chemotherapy administration is thought to provide better fluid
distribution than postoperative IP chemotherapy by avoiding postoperative adhesions and
the development of preferential intraperitoneal pathways for perfusion fluid.(38)
However, inflammation and vascular injury accompanying surgery may contribute to
altered pharmacokinetics, and potentially decreased pharmacokinetic advantage, by
increasing direct communication between the systemic circulation and the peritoneal
fluid.(39, 40)
Several rationales have been advanced for hyperthermic drug administration.
Hyperthermia has been shown in vitro to have direct cytotoxic effects, as well as to work
synergistically with some chemotherapy drugs.(41-43) It has been suggested that
hyperthermia contributes to greater tissue penetration of chemotherapy from the
peritoneal surface.(44, 45) However, this claim appears to be based on two rat studies that
are not entirely convincing. One study demonstrated higher diaphragm and tumor nodule
drug concentrations with hyperthermic compared to normothermic cisplatin.(46) The
other showed higher drug concentrations in some intra-abdominal organs, but not in
diaphragm or abdominal wall with hyperthermic compared to normothermic
doxorubicin.(47) Neither reported tissue drug concentrations compared to distance from
the peritoneal surface.
It is plausible that hyperthermia causes increased tissue drug concentrations by increasing
drug exposure via the circulation, rather than by increased direct tissue penetration. This
mechanism is supported by preclinical and clinical data. Platinum concentrations in rat
peritoneal tumors after carboplatin treatment at elevated temperatures were similar for the
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IP and IV routes.(48) Patients who received IV 5-fluorouracil (5-FU) during
intraoperative HIPEC with doxorubicin and mitomycin C had increased 5-FU
concentrations in peritoneal fluid and tumor nodules compared to plasma, suggesting
augmented communication with the circulation.(49) Inflammation and vascular injury
accompanying surgery may also contribute to increased communication with the
circulation as compared to non-intraoperative outpatient IP chemotherapy.(39, 40)

Catheter-Administered Intraperitoneal Chemotherapy (CAIPEC)
Outpatient administration of IP chemotherapy is accomplished through surgically-placed
IP catheters. Catheter placement is usually done at the time of laparotomy for disease
resection.(50) Interventional radiology and laparoscopic IP catheter placement techniques
have also been described.(51, 52)
Following the placement of IP catheters, in the early post-operative and/or late postoperative period, room-temperature chemotherapy is infused through the IP catheters and
allowed to dwell indefinitely in the peritoneal space. A comparison of the
pharmacokinetics of HIPEC vs. CAIPEC in a small cohort of patients receiving both
suggested that the total intraperitoneal drug exposure and the pharmacokinetic advantage
over the course of perfusion was greater for CAIPEC than for HIPEC.(53) Furthermore,
the indefinite dwell time, as compared to the removal of drug at the end of HIPEC, allows
for even greater total intraperitoneal drug exposure. This may help explain why survival
in a rat colon cancer model was increased with early post-operative CAIPEC compared to
HIPEC.(54) To date, no human or animal studies have reported the peritoneal tissue
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distribution of IP drug following multiple cycles of CAIPEC, such as is recommended for
peritoneal carcinomatosis of ovarian origin.(55)
X-ray computed tomography (CT) peritoneography has previously been used in patients
receiving catheter-administered IP chemotherapy to assess for catheter failure and
infusate maldistribution.(56-60) However, no standard system has been established to
assess infusate distribution, and outcomes data from patients assessed with CT
peritoneography has not been reported. Radiologic response to IP chemotherapy was
reported in a series of 11 ovarian carcinoma patients stratified into 3 categories by
distribution of intraperitoneal Tc-99m, and was suggestive of better response in patients
with free-flowing infusate than in those with loculation, but overall survival was not
reported.(61)
Indications for Intraperitoneal Chemotherapy

Pseudomyxoma Peritonei
Pseudomyxoma Peritonei (PMP) is a rare disease characterized by mucinous ascites with
peritoneal surface spread, most often of appendiceal mucinous neoplasms.(62)
Historically, patients would often undergo repeated interval debulking surgeries and
sometimes chemotherapy for symptomatic relief, as the disease and symptomatic ascites
would invariable recur with transition to more aggressive histologic characterisitcs at
repeat surgeries.(63, 64)
The current standard of care for PMP is cytoreductive surgery with HIPEC.(65) No
randomized controlled trials or comparative studies have been performed to date to assess
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the efficacy of cytoreductive surgery with HIPEC for PMP. However, a multicenter
retrospective analysis showed marked improvement in survival and recurrence compared
to historical controls.(66)

Peritoneal Carcinomatosis of Gastrointestinal Origin
Approximately 10% of colorectal cancer (CRC) patients present with peritoneal
carcinomatosis (PC) at the time of diagnosis, and 25% of patients develop PC at
recurrence; after liver recurrence, peritoneal surface spread is the most common site for
tumor recurrence in CRC.(67, 68) Likewise, PC may be present in 5% to 20% of patients
undergoing potentially curative resection of gastric cancer.(69) The prognosis in these
cases is generally dismal, as median survival with 5-fluorouracil-based systemic
chemotherapy is between 6 and 16 months.(67, 70, 71)
Several experienced groups now recommend HIPEC for PC of gastrointestinal
origin.(72-75) These recommendations are supported by one randomized controlled study
in CRC, one randomized controlled study in gastric cancer, and a number of case-control
and single-arm studies.(76-79)

Advanced Ovarian Carcinoma
Ovarian carcinoma is the leading cause of death from gynecologic malignancies in the
U.S.(80) The high rate of mortality is in part attributable to the large proportion of
ovarian carcinomas, up to 89%, that are advanced (Stage III or Stage IV) at the time of
diagnosis, including those that have spread over peritoneal surfaces.(81)
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The strongest support for the use of CAIPEC is in the treatment of advanced ovarian
carcinoma; meta-analysis in a recent Cochrane review showed increased overall and
disease-free survival for patients treated with IP chemotherapy.(82) Despite this evidence,
many advanced ovarian carcinoma patients who might benefit from IP chemotherapy are
not offered it, largely depending on physician experience and preferences. Physician
perceptions of IP chemotherapy are shaped in part by beliefs about biodistribution of IP
chemotherapy, some of which are based on incomplete evidence. One article criticized IP
chemotherapy for advanced ovarian cancer, stating, “It is well known that the higher
tumor concentration observed with the i.p. administration of cisplatin only reaches to a
depth of 1–2 mm.”(83) This conjecture (which was unsupported in that manuscript by
any references), may have been based on a study of HIPEC in humans, a study of IP
cisplatin dwelling for 7 days in rats, and theoretical calculations.(21, 26, 27) None of
these studies directly address the recommended regimen for advanced ovarian carcinoma,
six 3-week cycles of platinum-based intraperitoneal chemotherapy.(55)
Less data is available to support the use of HIPEC in advanced ovarian carcinoma,
although results from some non-randomized studies support its use, and it is a subject of
ongoing investigation.(84-88)

Malignant Peritoneal Mesothelioma
Malignant mesothelioma is a rare, seldom-curable tumor of the pleura or the peritoneum
whose origin has generally been linked to asbestos exposure.(89) Several experienced
groups recommend HIPEC as part of the standard of care for malignant peritoneal
mesothelioma (MPM).(30, 90-93) While no head-to-head trials have been performed,
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overall and progression-free survival in reported HIPEC series compares favorably with
those of systemic chemotherapy for MPM.(94-96)
Clinical Results of Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma
Three large series of MPM patients (two single-institution series and one multi-institution
report, including patient series from 8 institutions, some of which had been previously
reported) have been identified (Table 2). Several factors were noted to predict better
progression-free and overall survival in these patients; these prognostic factors are
summarized in Table 3.
Table 2. Intraperitoneal chemotherapy series for malignant peritoneal mesothelioma.

Investigator, Institution

Chemotherapy

Median

1-year

3-year

5-year

year

Modality, drug, n

Survival

survival

survival

survival

92 months

86%

59%

59%

Alexander ,
2003 (94)

NIH

Intraoperative
HIPEC, Cisplatin, 49
Postoperative
5-FU and Paclitaxel,
35
Total, 49
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Sugarbaker,
2009 (96)

Multiple

Intraoperative
HIPEC, Cisplatin and
Doxorubicin, 311
Intraoperative
HIPEC, Cisplatin and
Mitomycin C, 14
Intraoperative
HIPEC, Cisplatin, 19
Intraoperative
HIPEC, Mitomycin
C, 26
Intraoperative
HIPEC, Other, 2
Postoperative,
Cisplatin and
Doxorubicin, 16
Postoperative,
Paclitaxel, 77
Postoperative, Other,
1
Total, 405

53 months

81%

60%

47%

12

Chabot (95)

Columbia

Outpatient

University

Gemcitabine,
Cisplatin,
Doxorubicin,
Interferon
Outpatient Cisplatin,
Doxorubicin,
Interferon
Intraoperative
HIPEC, Cisplatin and
Mitomycin, 39
Total, 39

55 months

80.9%

61.7%

48.9%
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Table 3. Statistically-significant prognostic factors.
Investigator

Prognostic Factor

Analysis

P-value

Alexander (94)

Age < 60

Cox: Overall survival

0.034

Sugarbaker (96)

Age < 50

Univariate: Overall survival

0.003

Sugarbaker (96)

Female sex

Univariate: Overall survival

<0.001

Alexander (94)

No deep invasion

Cox: Overall survival

0.041

Cox: Progression-free survival

0.003

Cox: Overall survival

0.032

Alexander (94)

Residual disease <1
cm

Sugarbaker (96)

Cytoreduction score

Univariate: Overall survival

<0.001

Sugarbaker (96)

Epithelioid histology

Univariate: Overall survival

0.003

Chabot (95)

Epithelioid histology

Univariate: Overall survival

<0.001

Sugarbaker (96)

No lymph node

Univariate: Overall survival

0.008

Univariate: Overall survival

0.013

metastasis
Sugarbaker (96)

No extra-abdominal
metastasis
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Our protocol for the treatment of MPM includes initial debulking surgery with HIPEC
(41°C over 1 hour, after which drug is removed), then 6 cycles of CAIPEC (room
temperature, indefinite dwell-time), and a second debulking surgery with HIPEC (Dr.
Robert Taub, personal communication). This allowed us to obtain tissue samples from
patients during the initial surgery immediately after their first HIPEC, and during the
second surgery before HIPEC (but after 6 cycles of CAIPEC) and immediately after
HIPEC.
Initial debulking surgery prior to IP chemotherapy is performed with a goal of removing
all tumor nodules greater than 0.5 cm in depth or plaques greater than 0.5 cm in diameter,
as residual disease greater than 0.5 cm has been associated with adverse outcomes, in
peritoneal carcinomatosis in general and MPM in particular.(94, 96, 97) As a standard
assessment of catheter function and infusate distribution, many of these patients
underwent CT peritoneography.(98)
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II. Hypothesis and Aims
Our overall goals were to better characterize the sequence of events that are theorized to
lead from the pharmacokinetic advantage associated with intraperitoneal chemotherapy
(i.e. high local drug concentrations with lower systemic concentrations), to improved
local cytotoxicity with decreased systemic side effects, to better disease control and
therefore better survival. We used pharmacokinetic, radiologic and clinical parameters to
measure these purported effects.
In a previous study, the absorption of oxaliplatin during HIPEC was associated with body
mass index (BMI).(16) We sought to confirm or disconfirm and extend these results in
order to determine whether the dosing of intraperitoneal chemotherapy on the basis of
BSA, as is standard in most institutions, resulted in equivalent or predictably disparate
pharmacokinetic parameters for patients of various sizes, as measured by BMI or BSA.
We investigated this question in patients undergoing HIPEC with oxaliplatin for MPM
and other diseases.
The direct tissue penetration of platinum-based chemotherapy drugs has previously been
reported in in vitro and animal models, with treatment durations up to 1 week.(20-23, 25,
81) A study of tissue penetration of cisplatin in patients undergoing HIPEC used
antibody-detection of cisplatin-DNA adducts rather than direct imaging of the drug.(26)
None of these adequately address the tissue penetration of multiple cycles of CAIPEC
over the course of several months, as is used clinically. We sought to compare the depth
of direct tissue penetration of platinum-based chemotherapy drugs in HIPEC versus
CAIPEC in patients treated with both for MPM using direct imaging of tissue platinum.
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Finally, we sought to determine whether distribution of CAIPEC, as measured by
quantitative CT peritoneograms, were associated with overall survival and/or
complications as manifested by post-treatment GFR in patients treated with cisplatinbased IP chemotherapy, a regimen known for its side effect profile including
nephrotoxicity.
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III. Methods
Patients
Retrospective chart review identified 38 patients who underwent CT peritoneography
while receiving IP chemotherapy between February 2000 and August 2011. Baseline
characteristics of the 38 patients are reported in Table 4.
Table 4. Baseline characteristics of peritoneogram cohort.
Characteristic

Patients
(N=38)

Female sex – number [%]

19 [50%]

Age in years – median [range]

61 [21-83]

Body Surface Area in m2 – mean [SD]

1.92 [0.25]

Histologic subtype – number [%]
Epithelioid

34 [89%]

Biphasic

4 [11%]

Residual disease >0.5 cm – number [%]

10 [26%]

On an IRB approved protocol and with informed consent, peritoneal fluid and blood
samples were collected during closed-technique HIPEC in 10 patients receiving
oxaliplatin for pseudomyxoma peritonei (n=5), malignant peritoneal mesothelioma (n=4),
or peritoneal carcinomatosis from colon cancer (n=1), and 7 patients receiving cisplatin
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for malignant peritoneal mesothelioma. Patients received a BSA-based oxaliplatin dose
of 250 mg/m2 in 5% dextrose carrier fluid or cisplatin dose of 100 mg/m2 in 0.9% saline,
titrated to achieve a flow rate of 1 L/min over a 60-minute chemoperfusion. Blood
glucose was recorded for 24 hours following HIPEC for patients receiving oxaliplatin.
Peritoneal cancer index (PCI) and completeness of cytoreduction (CC) scores were
determined for all patients.(99, 100)
On an IRB-approved protocol, we collected peritoneal tissue and contemporaneous blood
samples from 6 MPM patients receiving cisplatin or oxaliplatin HIPEC at first (n=2; both
cisplatin) or second surgery (n=4; 2 cisplatin and 2 oxaliplatin). All second surgery
patients had received intraperitoneal cisplatin as outpatients. The median age of the
patients was 63 years (range 39-79). Four were male and 2 were female. Five patients had
epithelioid disease and one had biphasic disease.
Plasma and Peritoneal Perfusate Platinum Content
Blood samples were collected and centrifuged, and blood plasma isolated by Joshua
Leinwand and delivered to the Graziano lab for spectrophotometric analysis. Peritoneal
perfusate samples were collected and centrifuged, and the supernatant isolated by Joshua
Leinwand and delivered to the Graziano lab for spectrophotometric analysis. In the
Graziano lab, diluted plasma and peritoneal perfusate samples (in 2% HNO3, 1%
Methanol, 0.2% Triton 100-X) were analyzed for Pt concentrations using a Perkin-Elmer
Elan DRC II (Perkin Elmer, Shelton, CT) Inductively Coupled Plasma
Spectrophotometer (ICP-MS) equipped with an AS 93+ autosampler. The platinum
concentration of calibration standards was chosen to cover the expected range of
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platinum concentrations in the diluted plasma samples: 1, 5, and 10ug/L. Matrixinduced interferences were corrected using an iridium internal standard to match the mass
and ionization properties of the platinum. Stock internal standard spiking solution was
prepared and added to all calibrators and samples in the same concentration, 50 ng Ir per
tube. After the initial instrument calibration, quality control samples (QC-plasma spiked
in our laboratory and serum samples of known Pt concentration provided by Institut de
Sante Publique du Quebec) were run. To control instrument drift over the period of
running hours, we ran QC samples every 10-15 samples, and recalibrated if QCs didn’t
meet quality control criteria (+ 10% of target values).
Peritoneal Tissue Platinum Content
Peritoneal tissue samples were collected intraoperatively and stored at -70˚C in frozen
tissue matrix by Joshua Leinwand, and then delivered to the Borczuk lab for sectioning.
In the Borczuk lab, 20-micron-thick sections of each peritoneal tissue sample were
cryosectioned and deposited on Ultralene windows for x-ray fluorescence microscopy.
These sections were delivered to the Miller lab. In the Miller lab, the platinum contents of
the samples were imaged using x-ray fluorescence microscopy at beamline X27A at the
National Synchrotron Light Source. X-ray fluorescence spectra were collected using an
x-ray excitation energy of 12 keV using a Si(111) channel-cut monochromotor. The
monochromatic beam was then collimated to 350 µm × 350 µm and then focused to
approximately 6 µm × 10 µm using Rh-coated silicon mirrors in a Kirkpatrick-Baez (KB)
geometry. The sample was placed at a 45° angle to the incident x-ray beam and x-ray
fluorescence was detected with an energy dispersive, 9 element germanium array detector
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(Canberra, Meriden, CT) oriented at 90° to the incident beam. The sample was
approximately 6 cm from the detector. A light microscope objective (Mitutoyo, M Plan
Apo 5X) was coupled to a digital CCD camera for sample viewing. Energy dispersive
spectra were collected by raster scanning the sample through the x-ray beam using a
dwell time of 30 s/pixel and a step size of 4 µm to provide oversampling. The intensity
for platinum was quantified by integrating the area under the curve for the peak in the xray fluorescence spectrum (Kα = 66832.9 eV).
A semi-automated computer program developed at the National Synchrotron Light
Source identified regions-of-interest (ROIs) at the area of highest x-ray fluorescence
intensity at the peritoneal surface. The average platinum concentrations in these ROIs
were compared to the average platinum concentrations in the entire samples. Plots of xray fluorescence intensity versus distance from the peritoneal surface were produced by
drawing a region-of-interest polygon around each tissue sample and then summing
fluorescence counts for each horizontal section as a function of vertical distance. We
defined the depth of tissue penetration as the distance from the peritoneal surface at
which the average tissue platinum concentration fell below the contemporaneous plasma
platinum concentration.
Peritoneogram Imaging and Computer-Aided Volume and Surface Area Quantification
After injection of between 100cc and 500cc of diluted iohexol contrast into IP catheters
with patients in supine or semi-Fowler position, patients underwent standard
abdominopelvic CT scans. Smaller volumes of contrast were used in patients who
experienced pain or pressure with injection. CT scans were performed with patients in the
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supine position. Contrast-filled compartments are identifiable based on higher density
than surrounding structures on CT images. An in-house segmentation algorithm was
developed by the Schwartz lab in the Matlab programming language and applied to assist
in calculating volumes and surface areas of the compartments in this work (Dr. Lawrence
Schwartz, personal communication).
Joshua Leinwand manually selected a region-of-interest (ROI) enclosing all contrastfilled compartments on a single image. Localization followed by segmentation of each of
the compartments inside the ROI were then carried out automatically by the developed
algorithm. Once the segmentation was completed on an image, the result was propagated
to neighboring images, with automatic segmentation of the contrast-filled compartments.
This process continued iteratively until all compartments were segmented. To ensure
correct results, computer-generated compartment contours were superimposed on the
original images for inspection and modification as needed by Joshua Leinwand. These
images were reviewed by radiologists Dr. Lawrence Schwartz and/or Dr. Saravanan
Krishnamoorthy.
Once the segmentation was finalized, volumes and surface areas of the compartments
were automatically calculated. The compartment volume was calculated by multiplying
the total number of all compartments’ voxels and the image resolutions along x- (inplane), y- (in-plane) and z- (axial) directions. The compartment surface area was defined
as the sum of the interface areas of all compartment voxel sides facing non-compartment
voxels, where the area of a voxel side is calculated by multiplying the image resolutions
along the two directions spanning the plane at which the voxel side resides.
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The computer algorithms and a number of manual interaction functions such as selection
of ROI and modification of suboptimal computer results were integrated into a userfriendly image viewing system developed with the Matlab computer language by the
research group.
Statistical Analysis
For the 60 minute duration of HIPEC (samples at 10, 30 and 60 minutes) and 24 hour
blood glucose levels, area under concentration-time curve (AUC) was calculated by
Trapezoidal Rule, BSA determined by DuBois & Dubois formula, and pharmacokinetic
advantage by (AUC[peritoneal fluid]/AUC[plasma]).(101)
All statistical analysis was performed by Joshua Leinwand using SAS Version 9.2. The
LIFETEST procedure was used to produce the Kaplan-Meier survival estimates for all
patients and to compare survival by volume of residual disease (>0.5cm vs. <0.5cm). In
order to determine whether the presence of bulky disease was independent of
peritoneogram parameters and GFR, the TTEST procedure was used to test for
differences in mean surface area and volume of the contrast-filled compartment as well as
pre- and post-treatment GFR between patients with residual disease >0.5cm vs. those
with residual disease <0.5cm after initial tumor debulking surgery. Univariate Cox
models were conducted using the PHREG procedure for survival. In addition to the
surface area and volume of the contrast-filled compartment, any covariate with a P-value
< 0.1 in the univariate analysis was selected for multivariate analysis. Overall survival
was measured from IP catheter placement.
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Linear regression analyses with post-treatment GFR as the outcome measure were
conducted using the REG procedure. The regression models included pre-treatment GFR,
BSA (since cisplatin is dosed based on BSA), the surface area and volume of the
contrast-filled compartment, and two-way interactions between BSA, surface area or
volume, with only statistically significant (p<0.05) two-way interaction terms retained in
the final model. Pre- and post-treatment GFR were calculated from, respectively, the last
serum creatinine measured before IP catheter placement and the first serum creatinine
measured after IP catheter removal, by Cockgroft-Gault formula.(102) BSA was
calculated from the height and weight at the time of IP catheter placement by Mosteller
formula.(103)
Three patients underwent CT peritoneography twice. For these patients, we used the
mean surface area and volume of the contrast-filled compartment from the two CT
peritoneograms.
For HIPEC pharmacokinetic data, linear regression with cisplatin plasma AUC as the
outcome measure and BSA as the independent variable was conducted using the REG
procedure.
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IV. Results
Quantitative CT Peritoneography
Examples of computer-aided peritoneogram analysis images are presented in Figure 1.
Median overall survival by Kaplan-Meier analysis, pre-treatment and post-treatment GFR
and computer-aided peritoneogram volume and surface area data are presented in Table
5. There were no statistically-significant differences in volume or surface area parameters
between patients with residual disease >0.5cm versus those with residual disease <0.5cm
after initial debulking. We therefore considered the peritoneogram parameters
independent of the volume of residual disease.
We used univariate Cox models to determine which covariates to include with volume
and surface area in the multivariate Cox model of overall survival. Four variables (age,
sex, histologic subtype and residual disease >0.5cm) had p<0.1 and were included in the
multivariate model. We found that, controlling for age, sex, histologic subtype and
residual disease, the surface area of the contrast-filled compartment had a positive
relationship with overall survival (p=0.0201) and the volume of the contrast-filled
compartment had a negative relationship with overall survival (p=0.0341, Table 6). In
terms of proportional hazards, controlling for the above covariates, a 1-standard-deviation
increase in surface area is predicted to result in a hazard ratio of 0.222 (95% CI: 0.063 –
0.790) and a 1-standard-deviation increase in volume is predicted to result in a hazard
ratio of 3.165 (95% CI: 1.090 – 9.193).
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We used linear regression with post-treatment GFR as the outcome, and included pretreatment GFR and BSA, along with volume and surface area as covariates, as well as the
two-way interaction between volume and BSA (the only two-way interaction to reach
statistical significance). We found that, controlling for pre-treatment GFR, BSA, surface
area and the interaction between volume and BSA, the volume of the contrast-filled
compartment had a statistically-significant positive relationship with post-treatment GFR
(p=0.0167, Table 7). The interaction between volume and BSA is illustrated in Figure 2.
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Table 5. Overall survival, GFR and CT peritoneography parameters.
Residual

Residual

Disease <0.5

Disease >0.5

cm

cm

48 [11-76]

62 [47-94]

5 [1-22]

<0.0001

96.0 [35.5]

101.9 [38.5]

79.5 [17.9]

0.0872

90.1 [42.6]

96.2 [46.4]

73.1 [24.1]

0.1444

Contrast-filled

558.4

582.5 [458.4]

491.0 [725.6]

0.6468

compartment volume

[532.0]

860.4 [912.7]

0.2062

Parameter

Overall survival (months)

Overall

P-value

– median [95% CI]
Pre-treatment GFR
(cc/min) – mean [SD]
Post-treatment GFR
(cc/min) – mean [SD]

(cm3) – mean [SD]
Contrast-filled

1261.7

1405.0

compartment surface area

[1158.5]

[1216.8]

(cm2) – mean [SD]
Patient outcomes following intraperitoneal chemotherapy and algorithm-derived
peritoneogram values. GFR, glomerular filtration rate; CT, computed tomography; CI,
confidence interval; SD, standard deviation.

27

Table 6. Univariate and Cox models with overall survival as outcome.

Covariate (Univariate model)

Hazard

95% CI

P-value

Ratio
Age (years)

1.038

0.998 – 1.079

0.0628

Sex (female vs. male)

0.319

0.119 – 0.858

0.0235

Body surface area (m2)

1.160

0.179 – 7.539

0.8764

Histologic subtype (biphasic vs. epithelioid)

20.798

4.419 –

0.0001

97.890
Residual disease (>0.5cm vs. <0.5cm)

11.685

3.785 –

<0.0001

36.074
Contrast-filled compartment volume (cm3)

1.000

0.999 – 1.001

0.3551

Contrast-filled compartment surface area

1.000

0.999 – 1.000

0.0907

(cm2)
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Covariate (Multivariate model)

Hazard

95% CI

P-value

Ratio
Age (years)

1.060

1.002 – 1.120

0.0424

Sex (female vs. male)

1.188

0.347 – 4.066

0.7835

Histologic subtype (biphasic vs. epithelioid)

4.502

0.810 –

0.0856

25.026
Residual disease (>0.5cm vs. <0.5cm)

7.657

1.991 –

0.0031

29.456
Contrast-filled compartment volume (cm3)

1.002

1.000 – 1.004

0.0341

Contrast-filled compartment surface area

0.999

0.998 – 1.000

0.0201

---

---

<0.0001

(cm2)

Overall model

All variables with p<0.1 in the univariate analysis were included in the multivariate
model. Overall survival was measured from the time of intraperitoneal catheter
placement. CI, confidence interval.
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Table 7. Multiple linear regression with post-treatment GFR as outcome measure.
Covariate (Linear Regression Model)

Estimated

P-value

Regression
Coefficient
Pre-treatment GFR (cc/min)

0.802

<0.0001

Body Surface Area (m2)

69.969

0.0182

Contrast-filled compartment volume (cm3)

0.154

0.0167

Contrast-filled compartment surface area (cm2)

-0.003

0.5893

Interaction between volume and body surface area -0.070

0.0260

Overall model

---

<0.0001

Multivariate linear regression model, including only those 2-way interactions with
p<0.05. GFR, glomerular filtration rate.
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Figure 1. Computer-aided quantitative peritoneogram images.
(a)

(b)

The contrast-filled compartments are outlined in red for (a) well-distributed and (b)
loculated intraperitoneal contrast.
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Figure 2. Predicted post-treatment glomerular filtration rate.

For a patient with a pre-treatment GFR of 100cc/min and a contrast-filled compartment
surface area set at the sample mean (1262 cm2), comparing body surface area set at the
sample mean + one standard deviation (Low, Average and High BSA) and contrast-filled
compartment volume set at the sample mean + one standard deviation (Low, Average and
High Volume).
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HIPEC Pharmacokinetics

Cisplatin
To validate whether the effect of BSA on post-treatment GFR was related to systemic
cisplatin levels, we analyzed the relationship between BSA and cisplatin plasma AUC in
7 patients undergoing HIPEC using linear regression. We found that higher BSA was
associated with lower plasma AUC during HIPEC (estimated regression coefficient = 89.7 mg•min/L/m2, p=0.0381).

Oxaliplatin
Baseline characteristics of all patients, peritoneal cancer index and completeness of
cytoreduction scores are listed in Table 8. One patient had a PCI score of 0, as he had
previously undergone cytoreduction without any gross disease recurrence, and HIPEC
only was performed, without any resection.
We examined perfusate volume, BSA and BMI as independent variables; of these, only
perfusate volume and BSA were significantly correlated. Overall pharmacokinetic
parameters and Pearson correlation coefficients with perfusate volume, BSA and BMI
and as independent variables are listed in Table 9. Higher perfusate volume was
associated with lower plasma oxaliplatin AUC (β = -30.7 mg•min/L2, p=0.0170). Higher
BSA was associated with lower plasma oxaliplatin AUC (β = -153.2 mg/m2•min/L,
p=0.0075), and with a greater pharmacokinetic advantage (β = 28.7 m-2, p=0.0198) over
the 60-minute duration of HIPEC. There were no statistically significant relationships
between perfusate volume and peritoneal fluid oxaliplatin AUC or pharmacokinetic
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advantage; or between BSA and peritoneal fluid oxaliplatin AUC; or between BMI and
any of the pharmacokinetic parameters. The relationships between BSA and oxaliplatin
pharmacokinetic parameters are depicted in Figure 3. There did not appear to be
differences in pharmacokinetics based on diagnosis, extent of peritonectomy or between
patients with greater or lesser burdens of disease, as measured by PCI with a cut-off of 7.
There were no statistically significant relationships between perfusate volume, BSA or
BMI and 24-hour glycemia or peak intra-operative blood glucose.
Table 8. Baseline characteristics, extent of disease and surgical treatment.
ID

Diagnosis

Age

Sex

PCI CC

(years)
1

Peritoneal

79

Pseudomyxoma

M

3

0

Right

Pseudomyxoma

Prior
Resections

None

Omentectomy

Omentectomy,

None

diaphragm
65

F

5

0

Pelvis

Peritonei
3

Resections

Peritonectomy

Mesothelioma
2

Extent of

TAH-BSO
57

F

4

0

Peritonei

Bilateral

Omentectomy,

paracolic

TAH-BSO

None

gutters
4

Pseudomyxoma

48

F

2

0

None

Peritonei
5

Colon Cancer

Right

TAH-BSO

hemicolectomy
61

F

12

0

None

Right
hemicolectomy,
TAH-BSO

None
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6

Peritoneal

63

F

2

0

None

Omentectomy

None

65

M

15

0

Right paracolic Omentectomy,

None

Mesothelioma
7

Peritoneal
Mesothelioma

gutter, Left

splenectomy

diaphragm
8

Pseudomyxoma

25

F

6

0

Peritonei

Bilateral

None

Omentectomy,

diaphragms,

Appendectomy,

Bilateral

Right salpingo-

paracolic

oophorectomy

gutters
9

Pseudomyxoma

63

F

15

0

Peritonei

Bilateral

Omentectomy,

diaphragms

splenectomy,

None

appendectomy,
TAH-BSO
10

Peritoneal

68

M

0

0

None

None

Mesothelioma
F, Female; M, Male; PCI, Peritoneal Cancer Index score; CC, Completeness of
Cytoreduction score; TAH-BSO, total abdominal hysterectomy – bilateral salpingooophorectomy.

Omentectomy
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Table 9. Pharmacokinetic parameters and Pearson correlation coefficents.
Mean [SD]

Correlation

Correlation

Correlation

with Perfusate

with BSA

with BMI

[P-value]

[P-value]

Volume

[P-value]
Perfusate Volume (L) 2.7 [0.8]

---

0.788 [0.0068]

0.130 [0.7205]

BSA (m2)

1.70 [0.17]

---

---

0.095 [0.7935]

BMI (kg/m2)

25.8 [4.6]

---

---

---

Plasma AUC

138.1 [33.1]

-0.728 [0.0170]

-0.782 [0.0075]

-0.054 [0.8820]

2412.9 [711.4]

0.112 [0.7590]

0.227 [0.5273]

-0.402 [0.2496]

18.6 [6.8]

0.587 [0.0744]

0.716 [0.0198]

-0.334 [0.3453]

(mg•min/L)
Peritoneal fluid AUC

(mg•min/L)
Pharmacokinetic
Advantage
BSA, body surface area; BMI, body mass index; AUC, area under the concentration-time
curve; β, estimated correlation coefficient.
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Figure 3. Linear regression plots of body surface area vs. oxaliplatin pharmacokinetic
parameters.
(a)
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(b)
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(c)

BSA (m2) vs. (a) peritoneal fluid AUC (mg•min/L) [p=0.5273], (b) plasma AUC
(mg•min/L) [p=0.0075], and (c) pharmacokinetic advantage [p=0.0198].
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Tissue Penetration of Intraperitoneal Platinum Drugs
Peritoneal tissue without macroscopic evidence of tumor involvement was collected from
6 patients. One patient had remaining macroscopic disease during HIPEC at first
surgery; we collected post-HIPEC tissue samples of both macroscopically normal and
tumor tissue from that patient. The depths of platinum penetration in those samples were
similar: 1.056 mm in normal tissue versus 1.060 mm in tumor tissue. The parameters
from that patient’s normal tissue were used in the following analysis.
Examples of the x-ray fluorescence microscopy images obtained from one patient’s
samples at second surgery, both pre-HIPEC and post-HIPEC, are shown in Figure 4.
Examples of the tissue and contemporaneous plasma platinum plots from that patient’s
second surgery, both pre-HIPEC and post-HIPEC, are shown in Figure 5. Measured
overall and peritoneal surface ROI tissue platinum concentrations are shown in Table 10.
Measured tissue sampling depths and platinum penetration depths are shown in Table 11.
Tissue platinum was highest from second surgeries post-HIPEC, lowest from first
surgeries post-HIPEC, and intermediate from second surgeries pre-HIPEC. Every sample
had higher platinum at the peritoneal surface; these were also highest from second
surgeries post-HIPEC, lowest from initial surgeries post-HIPEC, and intermediate from
second surgeries pre-HIPEC. The ratio of platinum concentrations in the peritoneal
surface ROI versus the overall sample was lowest from second surgeries pre-HIPEC, and
was similar from first surgery post-HIPEC and second surgery post-HIPEC.
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The median sampling depth of peritoneal tissue was 1.55 mm (range 1.04 – 2.36). The
platinum penetration depths were not reached in 7 of 10 samples, including all 4 of the
second surgery pre-HIPEC samples. Both of the first surgery cisplatin post-HIPEC
samples had measurable platinum penetration depths (of 0.26 mm and 1.06 mm), as did
one second surgery oxaliplatin post-HIPEC sample (1.63 mm).

Table 10. Overall and peritoneal surface platinum concentrations from all enrolled
patients (n=6).
Sample Time Point

First surgery, post-

Median Pt (ppm)

Median Pt (ppm)

Median Ratio [range] –

[range] – Entire

[range] –

Peritoneal Surface:

Sample

Peritoneal Surface

Entire Sample

5.2 [4.7 – 5.8]

11.3 [8.4 – 14.2]

2.1 [1.8 – 2.5]

16.0 [5.6 – 21.8]

25.9 [8.4 – 29.9]

1.6 [1.1 – 2.0]

26.1 [2.2 – 113.4]

40.4 [4.4 – 219.7]

2.0 [1.1 – 2.5]

HIPEC (n=2)
Second surgery, preHIPEC (n=4)
Second surgery, postHIPEC (n=4)
Pt, platinum; HIPEC, hyperthermic intraoperative intraperitoneal chemotherapy; ppm,
parts per million.
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Table 11. Peritoneal tissue sampling depth and depth of platinum penetration.

Pre-HIPEC
Drug, Surgery

Post-HIPEC

Sample

Pt Penetration Sample Depth (mm)

Pt Penetration

Depth (mm)

(mm)

(mm)

Cisplatin, 1st

---

---

1.170

0.258

Cisplatin, 1st

---

---

1.520

1.060

Cisplatin, 2nd

1.368

Not Reached

1.038

Not Reached

Cisplatin, 2nd

1.668

Not Reached

1.572

Not Reached

Oxaliplatin, 2nd

1.818

Not Reached

1.224

Not Reached

Oxaliplatin, 2nd

2.214

Not Reached

2.358

1.632

Pt, platinum; HIPEC, hyperthermic intraoperative intraperitoneal chemotherapy
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Figure 4. X-ray fluorescence microscopy images.

(a)

1

2

3

4
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1

2

3

4

(b)

Obtained from one patient at second surgery, both pre-HIPEC (a) and post-HIPEC (b).
Panel 1, visible light microscopy; Panel 2, Pt imaging in green; Panel 3, Pt imaging in
green with visible light subtracted; Panel 4, Pt imaging in green, Zn imaging in red, Ca
imaging in blue with visible light subtracted.
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Figure 5. Oxaliplatin concentration plots.
(a)
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(b)

Tissue and contemporaneous plasma platinum concentration plots obtained from one
patient at second surgery, both pre-HIPEC (a) and post-HIPEC (b).
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V. Discussion
Quantitative CT Peritoneography
Our data suggest that larger surface areas of the compartment available to chemotherapy
administered by IP catheters are associated with improved overall survival in MPM
patients. This is consistent with the rationale for IP treatment of peritoneal surfacespreading malignancies – direct drug contact with a larger peritoneal surface area means
that more drug is directly delivered to potential areas of tumor spread.(104) Controlling
for surface area, larger volumes were associated with decreased survival, suggesting that
a high surface area-to-volume ratio of the contrast-filled compartment is optimal. This is
consistent with the observation that loculated intraperitoneal compartments are more
spherical, while free-flowing intraperitoneal compartments have irregular edges
corresponding to the peritoneal organs, notably the small bowel. In addition, a higher
surface area-to-volume ratio ensures that a larger proportion of the infused chemotherapy
is in close proximity to peritoneal surfaces.
In the final multivariate Cox model, in addition to larger surface area and smaller volume,
younger age and residual disease <0.5cm were associated with improved overall survival,
consistent with previous studies.(94-96, 105, 106) In this analysis, histology and sex were
not statistically-significant predictors of overall survival, which may be attributable to the
fact that in our cohort all of the females had epithelioid disease and 18 of 19 females had
no residual disease >0.5cm, while all 4 patients with biphasic disease also had residual
disease >0.5cm.
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Statistical analysis showed no differences in measured peritoneogram volume or surface
area between patients with residual disease >0.5cm vs. <0.5cm, making it likely that the
peritoneogram parameters were independent of observed tumor volume. We therefore
included both groups of patients in the survival analysis. Indeed, the final multivariate
Cox model showed that the volume and surface area of the contrast-filled compartments,
and the presence of residual disease >0.5cm were all statistically-significant independent
predictors of overall survival. However, the relatively small number of patients with
residual disease >0.5cm limits our ability to draw conclusions about this subgroup.
Our data suggest that larger volumes of the compartment available to IP catheteradministered chemotherapy are associated with higher post-treatment GFR in MPM
patients, which is consistent with the physiology of the peritoneal diffusion barrier.
Elevated intra-abdominal pressure is associated with increased fluid transfer from the
peritoneal space; the major diffusion barrier is the blood vessel wall and surrounding
interstitium, rather than the anatomic peritoneum.(29) Although we have not directly
measured intra-abdominal pressures, it is possible that increased compartment volume are
associated with lower compartmental pressures, resulting in lower intravascular drug
levels and less cisplatin nephrotoxicity.
In the final multiple linear regression model, larger BSA was associated with higher posttreatment GFR, possibly because of lower systemic drug exposure. This is consistent with
our HIPEC pharmacokinetic data (in which free flow is assured, as chemoperfusion
occurs during surgery, before adhesions can form), which showed that higher BSA was
associated with lower cisplatin plasma AUC.
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The strongest clinical evidence for improved survival with cathether-administered IP
chemotherapy is in advanced ovarian carcinoma, including a large meta-analysis
suggesting improved overall and disease-free survival for patients who receive IP
chemotherapy.(82) The landmark GOG-172 trial for ovarian carcinoma reported a
significant difference in overall survival for patients receiving intraperitoneal
chemotherapy vs. intravenous chemotherapy (median overall survival 65.6 vs. 49.7
months, p=0.03 by intention to treat analysis); however, only 42% of those assigned to
intraperitoneal chemotherapy completed all 6 cycles, due chiefly to catheter-related
complications, as well as renal/metabolic toxicities, neuropathy and
nausea/vomiting/dehydration.(107, 108) Prognostic factors, not only of overall survival
but of potential chemotherapy-related toxicities, are needed to optimally plan IP
chemotherapy, given the high rate of discontinuation due to adverse events. For example,
patients at risk for cisplatin nephrotoxicity may be treated with less nephrotoxic drugs.
Our retrospective data suggest that quantitative CT peritoneography provides parameters
associated with overall survival (compartment surface area and volume) and posttreatment GFR (compartment volume) in MPM patients undergoing IP chemotherapy. It
is possible that these data reflect a selection bias in which patients might have been
chosen to undergo CT peritoneography because of clinical suspicion of catheter-related
complications. In addition, patients who experienced pain or pressure with injection
received lower volumes of contrast. It is likely that these symptoms indicated that the
volume available to intraperitoneal contrast was filled, but use of a standardized volume
for all patients would provide added validity. Finally, standard prone-position CT scans
were used; however, they may not have reflected the physiologic distribution of
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intraperitoneal chemotherapy for different body positions. Prospective studies should be
undertaken, using a standardized contrast volume with patients in multiple positions,
possibly undergoing low-dose CT, to confirm the prognostic value of CT
peritoneography, and to extend our findings to other diseases including advanced ovarian
carcinoma.
HIPEC Pharmacokinetics
BSA is an imperfect but useful proxy to calculate drug doses, because of its association
with circulating blood volume.(109) Likewise, BSA has been used to estimate peritoneal
volumes for peritoneal dialysis.(110) BSA has been shown to be a predictor of outcomes
following cardio-pulmonary bypass, likely because of the association between low BSA
and hemodilutional anemia in that setting.(111) We hypothesized that the
pharmacokinetics of HIPEC with oxaliplatin would be associated with BSA, due to its
known association with circulating blood volume and peritoneal volume.
Our results suggest that in patients who receive a BSA-based oxaliplatin dose and carrier
fluid volume titrated to achieve a desired flow rate, BSA is a predictor of systemic drug
exposure and pharmacokinetic advantage. This is partially explained by the inverse
relationship observed between perfusate volumes and systemic oxaliplatin levels, as
perfusate volume was found to correlate with BSA. Patients with higher BSA had lower
plasma oxaliplatin AUC over the 60-minute duration of HIPEC, and thus greater
pharmacokinetic advantage, possibly because they also had larger circulating blood
volumes with inadequate time for equilibration between the peritoneal and circulating
blood compartments. Further studies should examine whether these relationships hold for
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patients who receive a set volume of carrier fluid, or a BSA-based volume of carrier
fluid. We did not find that BMI was a significant predictor of pharmacokinetic
parameters. The present study differed from a previous study showing such a relationship
in terms of the patients’ diagnoses, the duration and technique of HIPEC, and surgical
procedures and technique.(16) We did not find obvious differences in pharmacokinetics
on the basis of diagnosis, disease burden, or extent of peritonectomy, consistent with
previous reports.(112)
We did not find statistically significant relationships between BSA or BMI and glycemia
in our 10 patients, but hyperglycemia was observed in all patients. Given the relatively
small amount of oxaliplatin degradation in sodium chloride solution over the usual
duration of HIPEC, use of normal saline in the perfusion circuit (after oxaliplatin
reconstitution in 5% dextrose), as has previously been described, may be considered.(14,
18)
The present study shows that BSA can be used to predict the pharmacokinetics of HIPEC
with oxaliplatin, likely due to the effects of circulating blood volume with inadequate
time for drug equilibration. With the exception of metabolic derangements due to
hyperglycemia, oxaliplatin HIPEC was well-tolerated by all patients, suggesting that the
range of systemic drug levels they experienced is safe. Patients with larger BSA, who had
lower systemic drug levels, should therefore be able to tolerate higher total doses of
oxaliplatin. This was a small cohort, however, and we did not prospectively analyze
toxicity or efficacy, making it difficult to make clinical recommendations on the basis of
our data alone. We therefore recommend further study of HIPEC dosing modified to
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achieve a desired intraperitoneal drug concentration for all patients, rather than a BSAbased total dose. For example, a system like ours, which titrates carrier fluid to achieve a
minimum flow rate (which results in an variability in intraperitoneal drug concentrations)
could be modified to use oxaliplatin at a set concentration, with the volume (and
therefore the total dose) titrated to achieve the desired flow rate (which would result in
equal intraperitoneal drug concentrations for all patients). Patients with larger BSA would
then receive a higher total dose of drug, but, based on our data, the greater
pharmacokinetic advantage in these patients would ensure that their systemic drug levels
would remain tolerable. This method of dosing is more consistent with the observation
that intraperitoneal oxaliplatin concentration, rather than total dose, is the chief
determinant of HIPEC pharmacokinetics.(113, 114)
These data do not address the most important biodistribution endpoint, namely
intratumoral drug concentrations, but instead uses peritoneal fluid concentration as a
proxy. Few tissue analysis studies have been undertaken, and more are needed to
optimize HIPEC administration and dosing in order to achieve the highest possible drug
levels in tumor cells.(115) Our measurements of tissue drug concentrations are discussed
below.
Tissue Penetration of Intraperitoneal Platinum Drugs
Our protocol for the treatment of MPM, with sampling of peritoneal tissues at first
surgery post-HIPEC and at second surgery pre-HIPEC and post-HIPEC, allowed us to
investigate the roles of HIPEC versus CAIPEC in peritoneal tissue platinum distribution.
In particular, the second surgery pre-HIPEC time point can be considered to primarily
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represent the contribution of CAIPEC to tissue platinum distribution, while the postHIPEC time point at first surgery represents the contribution of HIPEC alone, with the
post-HIPEC time point at second surgery representing the contributions of both to some
extent. This inference is supported by our findings, that the ratio of peritoneal surface
platinum to whole sample platinum was similar in both post-HIPEC time points while
lower in the second surgery pre-HIPEC samples, and that the depth of direct tissue
platinum penetration was reached only in post-HIPEC samples (both of those from first
surgery, and one of four from second surgery).
On the basis of these findings, we conclude that the direct tissue penetration depth of
platinum attributable to multiple courses of CAIPEC is greater, and the tissue distribution
of platinum more homogeneous, than that attributable to a single dose of HIPEC. Among
the factors that likely contribute to these differences are the differences in dwell time
(indefinitely for CAIPEC versus 60 minutes for HIPEC), which allows for more
equilibration of drug between the peritoneal fluid, peritoneal tissue and systemic
compartments in CAIPEC; and the vascular injury and inflammation that accompany
surgery in HIPEC but not CAIPEC, resulting in greater direct communication between
the peritoneal fluid and systemic circulation (potentially bypassing absorption in
peritoneal tissues).
The samples obtained from all patients were from macroscopically normal tissue, because
the removal of macroscopic disease before HIPEC has been shown to improve survival in
PC patients.(97) In one patient who could not be debulked of all macroscopic disease at
first surgery, depth of platinum penetration was nearly identical in tumor tissue and
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normal tissue, suggesting that our findings may be applicable to tumor tissue as well.
However, aberrant tumor tissue architecture and vasculature may in fact contribute to
different tissue drug distributions in some patients.(116, 117)
Our findings demonstrate more homogeneous peritoneal tissue distribution and greater
depth of tissue penetration of platinum-containing chemotherapy drugs in multiple
courses of CAIPEC (such as is recommended for the treatment of advanced ovarian
carcinoma) compared to single-dose HIPEC (such as is becoming more common for the
treatment of PC of GI origin). Therefore, the use of biodistribution data from HIPEC
studies should not be assumed to apply to CAIPEC, or vice versa.
Furthermore our results suggest that in patients who may benefit from HIPEC (such as
patients with MPM or PC of colorectal or gastric origin), a pharmacokinetic rationale
exists for even greater benefit from CAIPEC, since many failures of IP chemotherapy are
due to insufficient tissue penetration.(118) For MPM, which is not routinely cured by
HIPEC alone, and which is unlikely to be subject to a successful clinical trial due to its
rarity, CAIPEC should therefore be offered following debulking surgery with HIPEC.
For PC of colorectal or gastric origin, clinical trials should include a CAIPEC arm to
determine if there is a survival benefit of CAIPEC compared to systemic chemotherapy
following HIPEC.
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